

February 4, 2016



VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection

NAMUR, Belgium, Feb. 4, 2016 /PRNewswire/ --[VolitionRx Limited](#) (NYSE MKT: VNRX) today released a video to celebrate World Cancer Day and to offer a message of hope from the inspirational cancer survivor, explorer and campaigner, Sean Swarner. VolitionRx supported Swarner's most recent expedition to the South Pole as part of the Company's corporate social responsibility programme and to raise awareness of the importance of early detection of cancer, as well as to show that patients can lead a long full life after overcoming cancer.

Swarner reached the South Pole after trekking for six days and enduring temperatures of -80°C and equipment malfunctions. The video released today highlights some of the challenges faced by Swarner during his expedition and how the blood tests for cancer developed by VolitionRx could help improve patient outcomes through early detection.

In his teenage years, Swarner was diagnosed with two different, unrelated and deadly forms of cancer. After an incredibly poor prognosis through which he spent a year in a medically-induced coma, Swarner astonished his doctors when he survived both diseases. With only one functioning lung, Swarner became the first cancer survivor to summit Mount Everest and has since gone on to ascend the highest peaks on each continent, the "Seven Summits", as well as to complete the Hawaii Ironman World Championship. Swarner is also an international keynote speaker, who will be releasing his first of seven ebooks on February 16, 2016.

Sean Swarner commented, "As with all my expeditions, one of my aims in trekking to the South Pole was to demonstrate to people all over the world that cancer is not a death sentence and to raise awareness of the importance of early detection. The best way to survive cancer is to find it early through screening, which is why I have teamed up with VolitionRx. VolitionRx is a life sciences company focused on developing a simple, cost-effective blood test to accurately diagnose a broad range of cancers. Detecting cancer at an early stage means it can be managed and treated effectively. If you are prepared, you can fight it. As a cancer survivor with only one lung who made it to the South Pole, I want other cancer patients and people all over the world to hear a message of hope in my story."

Cameron Reynolds, Chief Executive Officer of VolitionRx, remarked, "Corporate social responsibility is a core part of VolitionRx, and we were excited to have the opportunity last year of working with two-time cancer survivor Sean Swarner and supporting his goal of trekking to the South Pole. Sean is an extraordinary, inspirational person who, through his challenges and campaigns, demonstrates what is possible through courage, determination

and pushing boundaries. We are very proud to support him and to celebrate World Cancer Day by releasing this video of his trek to the South Pole. In the past few months, VolitionRx has announced results of over 90% accuracy in detecting colorectal, pancreatic and lung cancer, and these studies indicate that our NuQ[®] tests work equally well for early-stage cancer as for advanced tumors. I firmly believe that until a cure is found, the best way to minimise the harm from cancer is early detection through simple blood-based screening tests."

To watch the video, see: <https://youtu.be/Z7qfaFxGnyY>

For more information on Sean Swarner visit www.seanswarner.com.

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream -- an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

Visit VolitionRx's website (www.volitionrx.com) or connect with us on [Twitter](#), [LinkedIn](#), [Facebook](#) or [YouTube](#).

Media Contacts

Anita Heward, VolitionRx
a.heward@volitionrx.com
Telephone: +44 (0) 7756 034243

Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
Telephone: +1 (508) 280-6592

Investor Contacts

Scott Powell, VolitionRx
S.Powell@volitionrx.com
Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group
lroth@theruthgroup.com
Telephone: +1 (646) 536-7012

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities

Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics[®], NuQ[®] and HyperGenomics[®] and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/volitionrx-and-cancer-survivor-sean-swarnar-celebrate-world-cancer-day-with-message-of-hope-for-cancer-survival-through-early-detection-300215161.html>

SOURCE VolitionRx Ltd